Concomitant DPP-4 inhibitor and GLP-1 receptor agonist therapy
Concurrent use of a DPP-4 inhibitor (including sitagliptin/Januvia) with a GLP-1 receptor agonist (including semaglutide/Ozempic) is not recommended due to lack of additional glucose-lowering benefit beyond the GLP-1–based therapy. [1]
Medication Selection Algorithm
- GLP-1 receptor agonist therapy (including semaglutide/Ozempic) should be used without a DPP-4 inhibitor (including sitagliptin/Januvia). [1]
- DPP-4 inhibitor therapy should be discontinued when GLP-1 receptor agonist therapy is initiated for ongoing glycemic management. [1]
Key Evidence Supporting This Recommendation
- The ADA Standards of Care state that concurrent use of DPP-4 inhibitors with a GLP-1 receptor agonist is not recommended because there is no additional glucose lowering beyond that of GLP-1–based therapy. [1]
- NICE guidance also recommends not using a GLP-1 receptor agonist together with a DPP-4 inhibitor. [2]
Monotherapy vs Combination Therapy
- A GLP-1 receptor agonist is recommended as the incretin-based component when used for glycemic management. [1]
- Addition of a DPP-4 inhibitor to a GLP-1 receptor agonist is not recommended because it does not provide incremental glycemic efficacy over the GLP-1 receptor agonist alone. [1]
Initiation Thresholds and Treatment Sequencing
- When therapy escalation requires an incretin-based agent, treatment should use a GLP-1 receptor agonist rather than adding a DPP-4 inhibitor to an existing GLP-1 receptor agonist. [1]
Common Pitfalls to Avoid
- Continuing a DPP-4 inhibitor after starting a GLP-1 receptor agonist increases regimen complexity without added glucose-lowering benefit. [1]
Targets and Goals of Therapy
- Glycemic goals should be pursued using effective glucose-lowering medication strategies that include GLP-1 receptor agonists when indicated, without combining them with DPP-4 inhibitors. [1]